16 September 2026 note archive · Item
Inhaled insulin (Afrezza): review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Inhaled insulin (Afrezza)
Scope and findings:
- Read current FDA prescribing information; added pediatric missed noninferiority endpoint, group sizes, CI and limited safety counts. Adult outcomes and access not independently rechecked in this pass.
- Corrected US-only availability. US pediatric 6+ approval is not extended to India/Brazil by inference. Region enum does not represent these two markets; body/rationale disclose them.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.